is a drug manufacturer operating in Japan. It is a subsidiary controlled by
Hoffmann-La Roche
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX ...
, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo.
Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and
CEO.
History
Timeline
This is a timeline of important events of Chugai Pharmaceutical.
[ ]
* 1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines
* 1927: Start of the first own production
* 1930: Salobrocanon, an analgesic (pain reliever) and antipyretic is launched
* 1937: Calcium bromide production begins
* 1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo
* 1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga
* 1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt
* 1946: Construction of the plant in Kamagiishi
* 1951: Guronsan®, a drug to detoxify and restore liver function is launched
* 1952: Varsan®, a perspiration insecticide is launched
* 1955: Chugai became a public company
* 1956: The stock is listed on the Tokyo Stock Exchange
* 1957: Construction of the Ukima plant
* 1960: Establishment of a research center (Takada Research Laboratory, Tokyo)
* 1967: Foundation of Fukushima Kasai Co Ltd.
* 1961 – Developed patents for synthesis of
vitamin A
Vitamin A is a fat-soluble vitamin and an essential nutrient for humans. It is a group of organic compounds that includes retinol, retinal (also known as retinaldehyde), retinoic acid, and several provitamin A carotenoids (most notably ...
* 1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
* 1971: Construction of the factory in Fujieda
* 1975: Picibanil®, a cancer drug is launched
* 1982: Opening of a branch in New York
* 1986: Opening of a branch in London
* 1989: Acquisition of Gen-Probe Incorporated (USA)
* 1990: Epogin® launched
* 1995 – Released acute promyelocytic sphere of
leukemia
Leukemia ( also spelled leukaemia and pronounced ) is a group of blood cancers that usually begin in the bone marrow and result in high numbers of abnormal blood cells. These blood cells are not fully developed and are called ''blasts'' or ...
drug treatment
Vesanoid®
* 1996 – Released anti-viral chemotherapeutic agent
Hivid® (
HIV
The human immunodeficiency viruses (HIV) are two species of '' Lentivirus'' (a subgroup of retrovirus) that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immu ...
reverse transcriptase inhibitor)
* 1997 – Released HIV protease inhibitor
Invirase®
* 1999 – Released
immunosuppressive agent
Cellcept®
* 2000 – Released
antiemetic
An antiemetic is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. The ...
drug
Kytril®, developed to combating the side effects of
chemotherapy
Chemotherapy (often abbreviated to chemo and sometimes CTX or CTx) is a type of cancer treatment that uses one or more anti-cancer drugs (chemotherapeutic agents or alkylating agents) as part of a standardized chemotherapy regimen. Chemothe ...
* 2001 – Produced anti-
influenza virus Tamiflu (Roche)
* 2002: Start of the alliance with Roche
* 2003: Xeloda®, a cancer drug is launched
* 2005: Actemra® launched
* 2007: Copegus®, an antiviral, Avastin®, a cancer drug, and Tarceva®, a cancer drug launched
* 2011 – Produced
Actemra®, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
* 2014: Launch of Kadcyla®, a cancer drug, Chugai Pharma China Co Ltd. founded
* 2015 – In March the company announced it would co-commercialise
Athersys's
stem cell therapy
Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. , the only established therapy using stem cells is hematopoietic stem cell transplantation. This usually takes the form of a bone-marrow transplantation, b ...
for
ischemic stroke
Stroke (also known as a cerebrovascular accident (CVA) or brain attack) is a medical condition in which poor blood flow to the brain causes cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, ...
s in Japan. The deal could yield upwards of US$205 million.
* 2016: Cooperation between Osaka University and Chugai
* 2018: Tecentriq®, a cancer drug is launched
* 2020 – FDA approved
satralizumab (Enspryng) for treatment of the
orphan disease neuromyelitis optica
See also
*
Biotech and pharmaceutical companies in the New York metropolitan area
References
External links
Chugai Pharmaceutical Co., Ltd. English version of company homepageThe transfer of operations of the Company
Roche
Pharmaceutical companies of Japan
Manufacturing companies based in Tokyo
Companies listed on the Tokyo Stock Exchange
Orphan drug companies
Japanese companies established in 1943
1943 establishments in Japan
{{japan-company-stub